- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02164721
Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy (MADIT-CHIC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
With the advent of new therapies and an increasing number of long-term cancer survivors, the incidence and consequently the interest in chemotherapy-induced cardiomyopathy (CHIC) have been increasing. CHIC is a dose-dependent cardiomyopathy and presents as congestive heart failure several months to years after the administration of chemotherapy and/or chest radiation that includes the heart.
Greater than one-half of the patients exposed to just this class of drugs will show evidence of cardiac dysfunction, with 5% presenting with overt symptomatic heart failure. The overall incidence of CHIC is significantly underestimated as within the US alone, greater than 60,000 patients receive just anthracyclines every year. Despite this, there is little data on their response to conventional heart failure therapy. There is some preliminary evidence from two small, retrospective case-series suggesting that patients with CHIC and evidence of conduction tissue disease (i.e. a wide electrocardiographic depolarization duration (QRS) may significantly benefit from cardiac resynchronization therapy (CRT).
MADIT-CHIC is a multicenter, non-randomized, prospective observational study. The primary aim is to determine if CRT-D (Defibrillator) in high-risk patients with chemotherapy-induced cardiomyopathy will significantly improve left ventricular ejection fraction (LVEF) by echocardiography within 6 months of initiating CRT without adversely affecting mortality.
The study will last 6 months and will be conducted in 10-15 clinical centers in the United States.
Following implantation of the CRT-D device (Defibrillator), patients will be followed for 6 months. The first follow-up contact will be by phone at which time study personnel will review the patient's health status. The last study contact will be a 6-month clinic visit. At the 6-month visit, the patient's health status will be reviewed, the functioning of the CRT-D (Defibrillator) will be tested and an echocardiogram will be conducted. After the 6-month visit, the study-required follow-up will have been completed and patients will continue to have CRT-D (Defibrillator) clinical follow-up based on their physicians direction.
During the course of the study, Subjects will as outlined in the inclusion criteria continue on stable optimal pharmacologic therapy for the cardiac condition that is guideline-based and may include one or more of the following medications: Loop diuretics, Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB), Aldosterone antagonists and/or Beta-blockers unless the subject is not indicated, contraindicated, or is intolerant of medication.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Cardiovascular Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Tampa, Florida, United States, 33606
- University of South Florida
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
New York, New York, United States, 10032
- New York Presbyterian Hospita/Columbia University Medical Center
-
Rochester, New York, United States, 14642
- Univeristy of Rochester Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 (or of legal age to give informed consent specific to state and national law) up to 80 years of age
- Male or Female
- Without clinical heart failure at initiation of chemotherapy/radiation-induced treatment for an underlying malignancy, but developed clinical heart failure (cardiomyopathy: reduced left ventricular ejection fraction (LVEF) with a left bundle branch block (LBBB)-type of conduction disturbance; see next inclusion item) 6 months or more after initiation of the chemotherapy without other evident cause of the cardiomyopathy.
Eligible for implantation of a CRT-D (cardiac resynchronization therapy-defibrillator) device according to one of the following options in currently available guidelines:
- Class 1: Left ventricular ejection fraction (LVEF) less than or equal to 35% AND sinus rhythm AND LBBB (left bundle branch block) with a QRS (electrocardiographic depolarization duration) duration greater than or equal to 150ms AND NYHA (New York Heart Association) class II, III or ambulatory IV symptoms on guideline-directed medical therapy
- Class 2a1: Left ventricular ejection fraction (LVEF) less than or equal to 35% AND sinus rhythm AND left bundle branch block (LBBB) with a QRS (electrocardiographic depolarization duration) duration 120-149ms AND New York Heart Classification (NYHA) class II, III or ambulatory IV symptoms on guideline-directed medical therapy
- Class 2a2: Left ventricular ejection fraction (LVEF) less than or equal to 35% AND sinus rhythm AND Non-left bundle branch block (LBBB) with a QRS(electrocardiographic depolarization duration) duration greater than or equal to 150ms AND New York Heart Classification (NYHA) class III or ambulatory IV symptoms on guideline-directed medical therapy
- On stable optimal pharmacologic therapy for the cardiac condition that is guideline-based and may include one or more of the following medications: Loop diuretics, Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB), Aldosterone antagonists and/or Beta-blockers unless the subject is not indicated, contraindicated, or is intolerant of medication.
Exclusion Criteria:
- Currently implanted pacemaker or implantable cardioverter defibrillator (ICD) device
- Previous implant with a CRT (cardiac resynchronization therapy)/CRT-D (cardiac resynchronization therapy-defibrillator) device
- Cardiac condition not presumed to be caused by chemotherapy
- Documented symptoms or hemodynamically unstable ventricular tachyarrhythmia
- On active chemotherapy (must be at least 6 calendar months after last chemotherapy)
- Permanent or chronic Atrial Fibrillation (AF), or cardioversion for AF within the past 3 calendar months before consent date
- Structural heart disease such as congenital heart disease, valvular heart disease, e.g., rheumatic valvular heart disease, amyloid heart disease, etc.
- Coronary artery bypass graft surgery or percutaneous coronary intervention within the past 3 calendar months before consent date
- Enzyme positive myocardial infarction within the past 3 calendar months prior to consent date
- Unstable angina requiring hospitalization, with diagnostic work up and intervention within the past 3 months prior to consent date
- Angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary intervention in the foreseeable future
- Class IV and expected to undergo transplant within study duration
- Current or past history of drug addiction or abuse that caused cardiomyopathy
- Pregnant or plans to become pregnant during the course of the trial.
- Recent cerebral vascular accident or transient ischemia attack within the previous 3 months prior to consent date
- Presence of any disease, other than the subject's cardiac or cancer disease, associated with a reduced likelihood of survival for the duration of the trial, e.g., uremia, liver failure, active malignant disease, etc.
- Participating in any other clinical trial
- Unwilling or unable to cooperate with the protocol
- Lives at such a distance from the clinic that travel for follow-up visits would be unusually difficult
- Does not anticipate being a resident of the area for the scheduled duration of the trial
- Unwilling to sign the consent for participation
- Physician does not allow participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: CRT-D (Defibrillator)
Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
|
The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Left Ventricular Ejection Fraction
Time Frame: 6 months post implant
|
The primary endpoint will be the change in left ventricular ejection fraction (LVEF) from baseline to six months
|
6 months post implant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With All-Cause Mortality
Time Frame: 6 months post implant
|
Number of Participants with All-Cause Mortality in CRT-D patients
|
6 months post implant
|
Effects of CRT Therapy on Left Ventricular Volume at End Diastole
Time Frame: 6 months post implant
|
Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end diastole (LVEDV) between baseline and six months
|
6 months post implant
|
Effects of CRT Therapy on Left Ventricular Volume at End Systole
Time Frame: 6 months post implant
|
Determine based on echocardiogram study if CRT therapy improves left ventricular volume at end systole (LVESV) between baseline and six months
|
6 months post implant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in New York Heart Association (NYHA) Functional Class
Time Frame: 6 months post implant
|
Improvement in NYHA functional class between baseline and six months (yes/no), ie.
change from NYHA class III to NYHA II.
|
6 months post implant
|
Change in Left Atrial Size
Time Frame: 6 months post implant
|
Change in left atrial size between baseline and six months
|
6 months post implant
|
Effects of CRT on Frequency of Heart Failure
Time Frame: 6 months post implant
|
Effects of CRT on the frequency of heart failure with end point of inpatient hospitalization with augmented treatment for heart failure
|
6 months post implant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Valentina Kutyifa, MD, PhD, University of Rochester
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MADIT-CHIC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathy
-
University of AberdeenNHS GrampianCompletedTako-tsubo CardiomyopathyUnited Kingdom
-
Capricor Inc.National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsUnknownHeart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)United States
-
University of California, IrvineWithdrawnDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive Cardiomyopathy | Mitochondrial Cardiomyopathy | Noncompaction CardiomyopathyUnited States
-
University Hospital HeidelbergCharite University, Berlin, Germany; Goethe University; University Medicine Greifswald and other collaboratorsRecruitingAmyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction CardiomyopathyGermany
-
Dennis M. McNamara, MD, MSNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPeripartum Cardiomyopathy, PostpartumUnited States
-
University Medical Center GroningenAstraZenecaCompletedHeart Failure | Cardiomyopathy, Familial | Phospholamban R14del CardiomyopathyNetherlands
-
German Heart InstituteDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)UnknownDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Restrictive Cardiomyopathy | Left Ventricular Noncompaction | Primary CardiomyopathyGermany
-
Wayne State UniversityChildren's Hospital of Philadelphia; Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive CardiomyopathyUnited States, Canada
-
University of Cape TownMedtronicSuspendedDilated Cardiomyopathy | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathySouth Africa
-
Hospital General Universitario Gregorio MarañonMinisterio de Sanidad, Servicios Sociales e IgualdadUnknownPrimary Idiopathic Dilated CardiomyopathySpain
Clinical Trials on Three-lead CRT-D (Defibrillator)
-
Associazione Portatori Dispositivi Impiantabili...RecruitingHeart Failure | Cardiac Resynchronization TherapyItaly
-
Abbott Medical DevicesCompleted
-
MedtronicActive, not recruitingHeart FailureUnited States, Spain, Greece, France, Portugal, Switzerland, United Kingdom, Italy, Slovakia
-
Tomsk National Research Medical Center of the Russian...Not yet recruitingHeart Failure | Left Bundle-Branch Block | Ischemic Cardiomyopathy | Left Ventricular Dysfunction | Non-ischemic Dilated Cardiomyopathy | Left Ventricle RemodelingRussian Federation
-
Medtronic Bakken Research CenterMedtronic; FRANCECompleted
-
Abbott Medical DevicesCompleted
-
University of RochesterCompletedSystolic Heart Failure | Atrial Fibrillation (Permanent)United States
-
Abbott Medical DevicesCompleted
-
Biotronik, Inc.University of ZurichTerminatedHeart Failure | Ventricular DyssynchronyUnited States, Denmark, Israel, Germany, Australia, United Kingdom, Netherlands, France, Belgium, Czechia, Italy, Austria, Spain, Poland, Canada, Portugal, Switzerland